> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oral safiglipron was non-inferior to dapagliflozin on HbA1c, and superior at 90 mg
- URL: https://www.coios.me/oral-safiglipron-was-non-inferior-to-dapagliflozin-on-hba1c/
- Published: 2026-10-06T12:58:48.000Z
- Updated: 2026-10-06T17:08:49.000Z
- Description: In a double-blind phase 3 trial in adults with type 2 diabetes, the once-daily oral small-molecule GLP-1 receptor agonist safiglipron was non-inferior to dapagliflozin for HbA1c reduction at all doses tested and superior at 90 mg, with similar modest weight loss.
- Author: Daniel Ryan
- Tags: Healthcare today, Obesity, diabetes and GLP-1, #peer-reviewed, #new, #item, #source-2026-10

A randomised, double-blind phase 3 trial compared once-daily oral safiglipron, a small-molecule GLP-1 receptor agonist, with dapagliflozin in adults with type 2 diabetes. Safiglipron was non-inferior for HbA1c reduction at every dose tested and superior at 90 mg, with greater improvement in glycaemic control overall. Weight loss was similar and modest in both arms, and the safety profile was reported as acceptable.

*Why it is interesting: A phase 3 comparison of an oral small-molecule GLP-1 agonist against a standard oral agent rather than placebo.*

Source

[Nature Medicine, 5 October 2026](https://www.nature.com/articles/s41591-026-04713-y?ref=coios.me)

Type

Peer-reviewed article

Design

Randomised, double-blind, active-comparator phase 3 trial of once-daily oral safiglipron versus dapagliflozin in adults with type 2 diabetes; sample size and duration not stated in the abstract

Verdict

New finding

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)